Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, was issued on January 5, 2026. The report covers the period ending December 31, 2025, and serves as a notification to the market regarding the Company's issued share capital and total voting rights in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial results report.
Material Changes
The filing discloses the Company's issued share capital as of December 31, 2025:
- Total issued shares: 4,315,445,026 Ordinary Shares of 31 1/2 pence each.
- Treasury shares held: 240,019,489 Ordinary Shares.
- Total voting rights: 4,075,425,537.
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly provides the denominator for shareholders to calculate their notification thresholds under FCA rules.
Investor Verification Checklist
- Verify the total voting rights count of 4,075,425,537 for compliance with FCA disclosure thresholds.
- Confirm the number of treasury shares (240,019,489) held as of December 31, 2025.
- Check subsequent filings for actual financial performance data, as this 6-K does not contain earnings or cash flow information.